Purpose: To report the benefits of rheolytic thrombectomy for treating aortic endograft thrombosis.
Methods: Of 40 patients who received the Ancure bifurcated endograft to treat abdominal aortic aneurysm (AAA) during a 9-month period, 6 (15%) patients (6 men; mean age 62.6 years, range 53-77) developed thrombosis of the endograft at an average of 9 weeks (range 1-20 months). Five patients were taking aspirin, and 3 were on warfarin therapy for atrial fibrillation. Immediately after angiography, rheolytic thrombectomy was used to remove the thrombus, followed by adjunctive procedures to treat the underlying pathology.
Results: Causes were kinking or extrinsic compression of the graft limb in 5 cases and thrombosis of the surgical closure site in a common femoral artery. Mechanical thrombectomy was successful in restoring circulation in all cases; thrombolysis was used in 1. All 6 patients had additional stents placed in the graft limbs, re-establishing patency. There was no mortality or recurrent thrombosis in a follow-up that has extended to 26 months, but 1 patient required additional stenting for subsequent focal kinking of a graft limb above the previously implanted stent.
Conclusions: Rheolytic thrombectomy can safely and effectively treat endograft thrombosis after endovascular AAA repair. Additional thrombolytic agents, angioplasty, and stenting may be needed to correct the underlying causes of the thrombosis. Prophylactic stenting of iliac limbs at the time of implantation in patients with complex anatomy may prevent thrombosis of unsupported bifurcated endografts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/152660280200900607 | DOI Listing |
J Vasc Surg Venous Lymphat Disord
January 2025
Department of Cardiovascular Surgery, Hitit University Erol Olçok Education and Research Hospital, Çorum, TURKEY.
Background: This study aimed to examine the early clinical outcomes of AngioJet rheolytic thrombectomy (RT) in patients with acute bilateral iliofemoral deep vein thrombosis (IFDVT), with a specific focus on the incidence of post-thrombotic syndrome (PTS).
Methods: From March 2021 to August 2023, sixteen consecutive patients with acute bilateral IFDVT treated with AngioJet RT at our center were evaluated. Primary outcomes include patency of the target veins, development of PTS, recurrent DVT, and procedure related death.
Vascular
December 2024
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Harapan Kita National Cardiovascular Center, Jakarta, Indonesia.
Background: Endovascular intervention by means of thrombolysis is emerging as a promising management of Acute Aortic Occlusion (AAO). This study aims to evaluate the outcomes of endovascular thrombectomy for AAO cases in a single-center tertiary hospital in Indonesia.
Methods: We review retrospectively AAO patients treated by Rheolytic thrombectomy ± stenting or TEVAR at our referral center from 2011 to 2024.
Int Angiol
November 2024
Department of Vascular and Endovascular Surgery, St. Franziskus Hospital, Muenster, Germany.
Background: The aim of this study is to evaluate the safety and feasibility of the AngioJet™ device in the endovascular treatment of visceral ischemia with stenotic or occlusive lesions.
Methods: Retrospective analysis of patients treated for visceral artery occlusion with thrombectomy using the AngioJet™ (Boston Scientific, MA, USA). Inclusion criteria: patients with stenotic or occluding lesion in visceral arteries including renal and mesenteric arteries, who received endovascular treatment with AngioJet™.
Acta Radiol
November 2024
Department of Radiology, College of Medicine, Jeonbuk National University, Jeonju, Republic of Korea.
Background: AngioJet rheolytic thrombectomy is associated with a higher risk of acute kidney injury due to its potential for inducing mechanical harm and intravascular hemolysis. However, previous studies have focused on a single disease entity.
Purpose: To identify predictors associated with acute kidney injury after AngioJet rheolytic thrombectomy across a range of disease entities.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!